Role of NPT2b in health and chronic kidney disease.
OBJECTIVE
Maintaining phosphate homeostasis is essential and any deviation can lead to several acute and chronic disease states. To maintain normal physiological levels, phosphate needs to be tightly regulated. This is achieved through a complex relationship of organ cross-talk via hormonal regulation of the type II sodium-dependent phosphate co-transporters. This editorial provides evidence of the importance of intestinal NPT2b in health and chronic kidney disease (CKD).


RESULTS
The advent of the different Npt2b knockout mice has increased our understanding of how the intestinal phosphate co-transporter contributes to the regulation of systemic phosphate. In addition, these studies have suggested that Npt2b may participate in the phosphate-sensing machinery important for organ cross-talk. Studies using Drosophila have expanded our knowledge of phosphate sensing mechanisms and may provide a foundation for delineating these pathways in humans. Several preclinical studies using different agents to modulate Npt2b, and clinical studies using nicotinamide, have provided evidence that Npt2b is a viable therapeutic target for the management of hyperphosphatemia.


CONCLUSIONS
Over the last couple of years, new experimental approaches have increased our understanding of the important role of Npt2b in maintaining phosphate homeostasis. In addition, several clinical studies have associated the detrimental effects of elevated phosphate with cardiovascular events, and decreased lifespan. Although several key questions about intestinal phosphate transport remain to be answered, it is clear that the intestine is an important player, with current evidence suggesting that it is a prime target for regulating phosphate uptake and improving health outcomes in CKD.
Tissue Protection and Repair, Sanofi-Genzyme R&D Center, Genzyme, A Sanofi Company, Framingham, Massachusetts, USA.
Yves
Y
Sabbagh
Susan C
SC
Schiavi
D000818:Animals; D000089703:Fibroblast Growth Factor-23; D005346:Fibroblast Growth Factors / Q000378:metabolism; D006706:Homeostasis; D006801:Humans; D054559:Hyperphosphatemia / Q000188:drug therapy / Q000503:physiopathology*; D007413:Intestinal Mucosa / Q000378:metabolism*; D010710:Phosphates / Q000378:metabolism*; D020239:Receptor Cross-Talk; D051436:Renal Insufficiency, Chronic / Q000378:metabolism*; D050614:Sodium-Phosphate Cotransporter Proteins, Type IIb / Q000235:genetics* / Q000378:metabolism*
D010710:Phosphates; D050614:Sodium-Phosphate Cotransporter Proteins, Type IIb; D005346:Fibroblast Growth Factors; D000089703:Fibroblast Growth Factor-23